• Clement Mifsud-BonniciEmail author
Part of the LIDC Contributions on Antitrust Law, Intellectual Property and Unfair Competition book series (LIDC)


In Malta, anti-competitive conduct is regulated by the Competition Act and also the Treaty provisions. The law is applied across the board in the pharmaceuticals industry, but there are no specific guidelines issued by the Malta National Competition Authority. From a regulatory perspective, Malta has a flexible approach to generics at all stages. Malta applies the Roche Bolar exemption to manufacturers based in Malta. In distribution and supply, the regulators issue licences for parallel importing and also allow pharmacists to dispense generics (despite references to originators). The government also actively pursues the purchase of generics and insists on the indication of the active ingredient in its procurement processes. Malta also applies de facto price control in the private sector through a voluntary price referencing agreement beween governement and stakeholders in the industry.

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.GANADO AdvocatesVallettaMalta

Personalised recommendations